
Hepatitis C: State of Medicaid Access

Prescriber Restrictions

An analysis of 2017 Fee-For-Service (FFS) Medicaid data demonstrates that several Medicaid programs have eliminated prescriber requirements for patients seeking to access hepatitis C (HCV) cures, while others highly restrict access.

2017 Medicaid FFS Prescriber Restrictions for HCV Treatment







Comparison of 2017 Managed Care Organization (MCO) and Fee-For-Service (FFS) Prescriber Restrictions

State	2017 MCO Prescriber Restrictions ¹	Total Patients Enrolled in Medicaid ²	% MCO ³	% FFS/ Primary Care Case Management (PCCM) ³	2017 FFS Prescriber Restrictions
Alabama	No MCO Program	883,695	N/A	100	No Restrictions
Alaska	No MCO Program	193,019	N/A	100	No Restrictions
Arizona	Varied: By or in Consultation with a Specialist-Specialist Mus	t 1,745,097	92.8	7.2	By or in Consultation with a Specialist
Arkansas	Prescribe No MCO Program	898,557	N/A	100	Specialist Must Prescribe
California	No Restrictions	12,182,095	84.6	15.4	No Restrictions
Colorado	By or in Consultation with a Specialist	1,399,170	8.6		By or in Consultation with a Specialist
Connecticut	No MCO Program	771,588	N/A	100	No Restrictions
Delaware	Specialist Must Prescribe	244,960	94.7	5.7	No Restrictions
DC	Varied: By or in Consultation with a Specialist-Specialist Musi Prescribe	N/A	76		By or in Consultation with a Specialist
Florida	By or in Consultation with a Specialist	4,357,190	93	7	By or in Consultation with a Specialist
Georgia	No Restrictions	1,718,560	69	31	No Restrictions
Hawaii	Varied: By or in Consultation with a Specialist-Specialist Musi Prescribe	t 346,198	99	1	By or in Consultation with a Specialist
Idaho	No MCO Program	293,207	N/A	100	By or in Consultation with a Specialist
Illinois	Varied: By or in Consultation with a Specialist-Specialist Musi	t 3,040,025	63.4	36.6	By or in Consultation with a Specialist
Indiana	Carve Out*	1,481,073	79	21	By or in Consultation with a Specialist
Iowa	Specialist Must Prescribe	636,840	96	4	Specialist Must Prescribe
Kansas	By or in Consultation with a Specialist	403,231	95	5	By or in Consultation with a Specialist
Kentucky	Varied: No Restrictions-Specialist Must Prescribe	1,256,677	91	9	By or in Consultation with a Specialist
Louisiana	Specialist Must Prescribe	1,449,244	70	30	Specialist Must Prescribe
Maine	No MCO Program	267,252	N/A	100	By or in Consultation with a Specialist
Maryland	Varied: By or in Consultation with a Specialist-Specialist Musi	t 1,290,980	80	20	By or in Consultation with a Specialist
Massachusetts	No Restrictions	1,621,297	53	47	No Restrictions
Michigan	Carve Out*	2,358,312	75	25	By or in Consultation with a Specialist
Minnesota	Varied: By or in Consultation with a Specialist-Specialist Musi Prescribe	t 1,044,472	75	25	By or in Consultation with a Specialist
Mississippi	By or in Consultation with a Specialist	672,073	70	30	By or in Consultation with a Specialist
Missouri	Carve Out*	967,477	51.2	48.8	No Restrictions
Montana	No MCO Program	260,931	N/A	100	Specialist Must Prescribe
Nebraska	No Restrictions	238,855	77	23	No Restrictions
Nevada	No Restrictions	631,370	77	23	No Restrictions
New Hampshire	Carve Out*	184,252	95.7	4.3	By or in Consultation with a Specialist
New Jersey	Specialist Must Prescribe	1,750,123	94.6	5.4	Restrictions Unknown
New Mexico	No Restrictions	781,857	88.2	11.8	No Restrictions
New York	Varied: No Restrictions-By or in Consultation with a Specialis	t 6,416,899	77.1	22.9	By or in Consultation with a Specialist
North Carolina	No MCO Program	2,030,268	N/A	100	No Restrictions
North Dakota	Restrictions Unknown	93,148	22	78	By or in Consultation with a Specialist
Ohio	Varied: By or in Consultation with a Specialist-Specialist Must Prescribe	t 2,788,908	88	12	Specialist Must Prescribe
Oklahoma	No MCO Program	802,957	N/A		By or in Consultation with a Specialist
Oregon	Varied: By or in Consultation with a Specialist-Specialist Must Prescribe		85.7		By or in Consultation with a Specialist
Pennsylvania Puerto Rico**	Varied: By or in Consultation with a Specialist-Specialist Must Prescribe		82.8 N/A	17.2 N/A	Specialist Must Prescribe By or in Consultation with a Specialist
Rhode Island	Carve Out* Specialist Must Prescribe	1,671,657	N/A	S	By or in Consultation with a Specialist Specialist Must Prescribe
South Carolina	Carve Out*	1 007 102	90	10	By or in Consultation with a Specialist
South Carolina South Dakota	No MCO Program	1,007,192	72.7 N/A	27.3 100	Specialist Must Prescribe
Tennessee	Carve Out*	1,474,763	100	N/A	Specialist Must Prescribe
	By or in Consultation with a Specialist		88		By or in Consultation with a Specialist
Texas Utah	Varied: No Restrictions-Specialist Must Prescribe	4,749,590 304,670	81.5		By or in Consultation with a Specialist By or in Consultation with a Specialist
	**.		ADM 100 A TO A	*	
Vermont Virginia	No MCO Program Varied: By or in Consultation with a Specialist-Specialist Musi	167,599 t 998,690	N/A 83		By or in Consultation with a Specialist By or in Consultation with a Specialist
	Prescribe				
Washington	Carve Out*	1,781,312	83		By or in Consultation with a Specialist
West Virginia	Carve Out*	557,580	63		By or in Consultation with a Specialist
Wisconsin	Carve Out*	1,037,696	67	33	No Restrictions
Wyoming	No MCO Program	60,075	N/A	100	No Restrictions

^{*&}quot;Carve Out" indicates when hepatitis C treatments have been removed from MCO coverage and FFS sets all Medicaid beneficiary requirements.

^{3 &}quot;Share of Medicaid Population Covered under Different Delivery Systems," The Henry J Kaiser Family Foundation, www.kff.org. July 1, 2016.





^{**} Puerto Rico operates a separate Hepatitis C Treatment Program through its Health Department and excludes therapy from its Medicaid program.

¹ Figures based on data from the 2016 "Hepatitis C: The State of Medicaid Access" survey.

² State Medicaid & CHIP Profiles, Medicaid.gov (July 2017). Note: Medicaid enrollment varies on a monthly basis.